Status:
NOT_YET_RECRUITING
Long-term Study to Evaluate Safety and Persistence of GF-CART01
Lead Sponsor:
GenomeFrontier Therapeutics TW Co., Ltd.
Conditions:
DLBCL - Diffuse Large B Cell Lymphoma
Follicular Lymphoma (FL)
Eligibility:
All Genders
Brief Summary
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
Detailed Description
This comprehensive long-term follow-up study is meticulously designed to assess the safety and persistence of GF-CART01. Subjects who participated in the initial study of GF-01-01 and received treatme...
Eligibility Criteria
Inclusion
- Subjects previously enrolled in the study of GF-CART01 (Protocol No.: GF-01-01) and received GF-CART01 infusion
- Subjects or their legal guardians must volunteer to participate in the study and sign the informed consent
- Willingness and ability to comply with protocol-stated requirements, instructions, and restrictions in the investigator's judgement
Exclusion
- None
Key Trial Info
Start Date :
May 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2041
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06985576
Start Date
May 1 2026
End Date
May 1 2041
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100